IVS1 -397T > C estrogen receptor α polymorphism is associated with low-grade systemic inflammatory response in type 1 diabetic girls

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Ryba Stanisławowska, Monika ^a   Rybarczyk Kapturska, Karolina ^a   Brandt, Agnieszka ^a   Myśliwiec, Małgorzata ^a   Myśliwska, Jolanta ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; INTERLEUKIN 10; INTERLEUKIN 6; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; CYTOKINE; ESTROGEN RECEPTOR ALPHA, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; IL10 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; VASCULOTROPIN A;

ADOLESCENT; ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENETIC VARIABILITY; GENOTYPE; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MENSTRUATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TH17 CELL; BLOOD; CASE CONTROL STUDY; CD4+ T LYMPHOCYTE; CYTOLOGY; GENETICS; METABOLISM; MICROCIRCULATION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; DIABETES MELLITUS, TYPE 1; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENOTYPE; HUMANS; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-6; MICROCIRCULATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; TH17 CELLS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84893197226     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/839585     Document Type: Article

References (44)

1. Tang L., Wang L., Liao Q., Genetic associations with diabetes: meta-analyses of 10 candidate polymorphisms. PLoS One 2013 8 7 e70301 10.1371/journal.pone.0070301
2. Quintero O. L., Amador-Patarroyo M. J., Montoya-Ortiz G., Rojas-Villarraga A., Anaya J.-M., Autoimmune disease and gender: plausible mechanisms for the female predominance of autoimmunity. Journal of Autoimmunity 2012 38 2-3 J109 J119 2-s2.0-84858752604 10.1016/j.jaut.2011.10.003
3. Rubtsov A. V., Rubtsova K., Kappler J. W., Marrack P., Genetic and hormonal factors in female-biased autoimmunity. Autoimmunity Reviews 2010 9 7 494 498 2-s2.0-77951878126 10.1016/j.autrev.2010.02.008
4. Nussinovitch U., Shoenfeld Y., The role of gender and organ specific autoimmunity. Autoimmunity Reviews 2012 11 6-7 A377 A385 2-s2.0-84858450790 10.1016/j.autrev.2011.11.001
5. Gleicher N., Barad D. H., Gender as risk factor for autoimmune diseases. Journal of Autoimmunity 2007 28 1 1 6 2-s2.0-33847083891 10.1016/j.jaut.2006.12. 004 (Pubitemid 46274179)
6. González D. A., Díaz B. B., Rodríguez Pérez Mdel C., Hernández A. G., Chico B. N., de León A. C., Sex hormones and autoimmunity. Immunology Letters 2010 133 1 6 13 10.1016/j.imlet.2010.07. 001
7. + regulatory T cell compartment. The Journal of Immunology 2004 173 4 2227 2230 2-s2.0-4043071317 (Pubitemid 39063075)
8. Tai P., Wang J., Jin H., Song X., Yan J., Kang Y., Zhao L., An X., Du X., Chen X., Wang S., Xia G., Wang B., Induction of regulatory T cells by physiological level estrogen. Journal of Cellular Physiology 2008 214 2 456 464 2-s2.0-37349033910 10.1002/jcp.21221 (Pubitemid 350309002)
9. + regulatory T cells during the follicular phase of the menstrual cycle: implications for human reproduction. The Journal of Immunology 2007 178 4 2572 2578 2-s2.0-33846899223 (Pubitemid 46233460)
10. +CD2 5 hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clinical and Experimental Immunology 2008 154 3 353 359 2-s2.0-55449111318 10.1111/j.1365-2249.2008.03810.x
11. + regulatory T cells in patients with type 1 diabetes from effects mediated by TNF. Cytokine 2011 55 3 353 361 2-s2.0-79960893564 10.1016/j.cyto.2011.05.006
12. + tregs are associated with inflammatory conditions in type 1 diabetic patients. Mediators of Inflammation 2011 2011 7 2-s2.0-79959196948 10.1155/2011/645643 645643
13. + regulatory T cells in infants of mothers with type 1 diabetes. Pediatric Diabetes 2012 13 5 400 407 2-s2.0-84856991276 10.1111/j.1399-5448.2012.00852.x
14. Ryba M., Malinowska E., Rybarczyk-Kapturska K., Brandt A., Myśliwiec M., Myśliwska J., The association of the IVS1-397T>C estrogen receptor α polymorphism with the regulatory conditions in longstanding type 1 diabetic girls. Molecular Immunology 2011 49 1-2 324 328 2-s2.0-82455204055 10.1016/j.molimm.2011.09.004
15. Targher G., Bertolini L., Zoppini G., Zenari L., Falezza G., Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy. Diabetic Medicine 2005 22 8 999 1004 2-s2.0-22644438381 10.1111/j.1464-5491.2005.01562.x (Pubitemid 41025995)
16. Goldberg R. B., Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. The Journal of Clinical Endocrinology and Metabolism 2009 94 9 3171 3182 2-s2.0-69949093803 10.1210/jc.2008-2534
17. Lim A. K., Tesch G. H., Inflammation in diabetic nephropathy. Mediators of Inflammation 2012 2012 12 146154 10.1155/2012/146154
18. Navarro-González J. F., Mora-Fernández C., The role of inflammatory cytokines in diabetic nephropathy. Journal of the American Society of Nephrology 2008 19 3 433 442 2-s2.0-40449113524 10.1681/ASN.2007091048 (Pubitemid 351355386)
19. Myśliwiec M., Balcerska A., Zorena K., Myśliwska J., Lipowski P., Raczyńska K., The role of vascular endothelial growth factor, tumor necrosis factor alpha and interleukin-6 in pathogenesis of diabetic retinopathy. Diabetes Research and Clinical Practice 2008 79 1 141 146 2-s2.0-37549045198 10.1016/j.diabres.2007.07.011
20. Aiello L. P., Wong J.-S., Role of vascular endothelial growth factor in diabetic vascular complications. Kidney International 2000 77 S113 S119 2-s2.0-0033852483
21. Schrijvers B. F., Flyvbjerg A., de Vriese A. S., The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney International 2004 65 6 2003 2017 2-s2.0-2442707596 10.1111/j.1523-1755.2004.00621.x (Pubitemid 38669987)
22. Ryba-Stanisławowska M., Skrzypkowska M., Myśliwska J., Myśliwiec M., The serum IL-6 profile and Treg/Th17 peripheral cell populations in patients with type 1 diabetes. Mediators of Inflammation 2013 2013 7 205284 10.1155/2013/205284
23. Kimura A., Kishimoto T., IL-6: regulator of Treg/Th17 balance. European Journal of Immunology 2010 40 7 1830 1835 2-s2.0-77954096689 10.1002/eji.201040391
24. Cook A., Th17 cells in inflammatory conditions. The Review of Diabetic Studies 2006 3 2 72 75
25. Bradshaw E. M., Raddassi K., Elyaman W., Orban T., Gottlieb P. A., Kent S. C., Hafler D. A., Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells. The Journal of Immunology 2009 183 7 4432 4439 2-s2.0-70449704670 10.4049/jimmunol.0900576
26. Honkanen J., Nieminen J. K., Gao R., Luopajarvi K., Salo H. M., Ilonen J., Knip M., Otonkoski T., Vaarala O., IL-17 immunity in human type 1 diabetes. The Journal of Immunology 2010 185 3 1959 1967 2-s2.0-77956398549 10.4049/jimmunol.1000788
27. + Th17 cells in patients with type 1 diabetes. Human Immunology 2013 74 6 701 707 10.1016/j.humimm.2013.01.024
28. American Diabetes Association, Diagnosis and classification of diabetes mellitus. Diabetes Care 2008 31 supplement 1 S55 S60 10.2337/dc08-S055 (Pubitemid 351520689)
29. Myśliwska J., Rutkowska A., Hak Ł., Siebert J., Szyndler K., Rachoń D., Inflammatory response of coronary artery disease postmenopausal women is associated with the IVS1-397T > C estrogen receptor α polymorphism. Clinical Immunology 2009 130 3 355 364 2-s2.0-59349119868 10.1016/j.clim.2008.09.017
30. Herrington D. M., Howard T. D., Bridget Brosnihan K., McDonnell D. P., Li X., Hawkins G. A., Reboussin D. M., Xu J., Zheng S. L., Meyers D. A., Bleecker E. R., Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation 2002 105 16 1879 1882 2-s2.0-0037161368 10.1161/01.CIR.0000016173.98826.88 (Pubitemid 34437611)
31. Herrington D. M., Howard T. D., Hawkins G. A., Reboussin D. M., Xu J., Zheng S. L., Bridget Brosnihan K., Meyers D. A., Bleecker E. R., Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. The New England Journal of Medicine 2002 346 13 967 974 2-s2.0-0037187926 10.1056/NEJMoa012952 (Pubitemid 34983246)
32. Sukovich D. A., Kauser K., Shirley F. D., DelVecchio V., Halks-Miller M., Rubanyi G. M., Expression of interleukin-6 in atherosclerotic lesions of male ApoE- knockout mice: inhibition by 17beta-estradiol. Arteriosclerosis, Thrombosis, and Vascular Biology 1998 18 9 1498 1505 2-s2.0-0031714562 (Pubitemid 28421889)
33. Pfeilschifter J., Köditz R., Pfohl M., Schatz H., Changes in proinflammatory cytokine activity after menopause. Endocrine Reviews 2002 23 1 90 119 2-s2.0-0036188807 10.1210/er.23.1.90 (Pubitemid 34185307)
34. Rachoń D., Suchecka-Rachoń K., Hak Ł., Myśliwska J., Effects of intranasal 17beta-estradiol administration on serum bioactive interleukin-6 and C-reactive protein levels in healthy postmenopausal women. Menopause 2006 13 5 840 845 2-s2.0-33748926604 (Pubitemid 44435040)
35. Schalkwijk C. G., Stehouwer C. D. A., Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clinical Science 2005 109 2 143 159 2-s2.0-23644439784 10.1042/CS20050025 (Pubitemid 41117297)
36. Benjamin L. E., Glucose, VEGF-A, and diabetic complications. The American Journal of Pathology 2001 158 4 1181 1184 2-s2.0-0035074539 (Pubitemid 32281279)
37. Ferrara N., Gerber H.-P., LeCouter J., The biology of VEGF and its receptors. Nature Medicine 2003 9 6 669 676 2-s2.0-0037699954 10.1038/nm0603-669 (Pubitemid 36749215)
38. Yoo S. A., Bae D. G., Ryoo J. W., Kim H. R., Park G. S., Cho C. S., Chae C. B., Kim W. U., Arginine-rich anti-vascular endothelial growth factor (anti-VEGF) hexapeptide inhibits collagen-induced arthritis and VEGF-stimulated productions of TNF-alpha and IL-6 by human monocytes. The Journal of Immunology 2005 174 9 5846 5855 2-s2.0-17844372767
39. Verthelyi D., Sex hormones as immunomodulators in health and disease. International Immunopharmacology 2001 1 6 983 993 2-s2.0-0035026467 10.1016/S1567-5769(01)00044-3 (Pubitemid 32434419)
40. Shelbaya S., Amer H., Seddik S., Allah A. A., Sabry I. M., Mohamed T., El Mosely M., Study of the role of interleukin-6 and highly sensitive C-reactive protein in diabetic nephropathy in type 1 diabetic patients. European Review for Medical and Pharmacological Sciences 2012 16 2 176 182 2-s2.0-84859486300
41. Huang Z., Yang B., Shi Y., Anti-TNF- α therapy improves Treg and suppresses Teff in patients with rheumatoid arthritis. Cellular Immunology 2012 279 1 25 29 10.1016/j.cellimm.2012.09.001
42. Miossec P., IL-17 and Th17 cells in human inflammatory diseases. Microbes and Infection 2009 11 5 625 630 2-s2.0-67349234068 10.1016/j.micinf.2009.04.003
43. Robak E., Kulczycka-Siennicka L., Gerlicz Z., Kierstan M., Korycka-Wolowiec A., Sysa-Jedrzejowska A., Correlations between concentrations of interleukin (IL)-17A, IL-17B and IL-17F, and endothelial cells and proangiogenic cytokines in systemic lupus erythematosus patients. European Cytokine Network 2013 24 1 60 68
44. Chung A. S., Wu X., Zhuang G., An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nature Medicine 2013 19 1114 1123 10.1038/nm.3291